Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592771 · ClinicalTrials.gov registry record · NA
THRIVE Breast Cancer App Study
A NA study of Breast Neoplasm Female, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 304
- Enrollment target
- 2
- Study locations
NCT03592771: Completed NA study of Breast Neoplasm Female, sponsored by Emory University.
NCT03592771 is a NA study of Breast Neoplasm Female that has completed, run by Emory University. The registered enrollment target is 304 participants, above the 142-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (114% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03592771, a NA study of Breast Neoplasm Female, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 304 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will test the use of a web-enabled app that is integrated directly with patients' electronic health records, with and without tailored feedback. The app-based intervention is designed to improve patient-provider communication outside of clinic visits, resulting in improved symptom management and adjuvant endocrine therapy adherence among diverse patients with hormone receptor-positive breast cancer. The researchers will evaluate the impact of the intervention on a comprehensive set of outcomes, including rigorous measures of long-term adherence, quality of life, and costs.
Primary Outcome
Medication adherence with prescribed AET (aromatase inhibitor or tamoxifen) is captured using an electronic monitoring pillbox (Wisepill).
Conditions Studied
Interventions
- BEHAVIORAL THRIVE App
- BEHAVIORAL Tailored Feedback Messages
Study Locations (2)
Tennessee
- West Cancer Center, Midtown - Memphis
- West Cancer Center, East Memphis - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
What the finished NCT03592771 record still lists
NCT03592771 is an interventional study that assigns participants to a tested intervention. The registered 304 participants enrollment target is mid-sized for trials with a published cap, above the 142-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Breast Neoplasm Female appearing as the primary indexed condition, and to 2 interventions - of which THRIVE App is the first listed.
NCT03592771 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03592771 about?
NCT03592771 is a clinical study titled "THRIVE Breast Cancer App Study". This study will test the use of a web-enabled app that is integrated directly with patients' electronic health records, with and without tailored feedback. The app-based intervention is designed to improve patient-provider communication outside of clinic visits, resulting in improved symptom managem...
What is the current status of trial NCT03592771?
This trial is currently completed. It is a NA study. The enrollment target is 304 participants. The study started on 2018-11-15. Estimated completion is 2022-06-30.
What conditions does trial NCT03592771 study?
This clinical trial studies the following conditions: Breast Neoplasm Female.
What interventions are being tested in trial NCT03592771?
The interventions under investigation include: THRIVE App (BEHAVIORAL), Tailored Feedback Messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT03592771?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03592771 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03592771's enrollment target sits among peer trials
304 2nd of 8 the highest of 8 other Breast Neoplasm Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
RECRUITING · NA
-
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
RECRUITING · NA
-
Study on Physical Activity's Relationship With Cancer and Cognition
COMPLETED · NA
-
Web-Base App To Improve Aromatase Inhibitor Adherence
COMPLETED · NA
-
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
COMPLETED · NA
-
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
- NCT06096844 · 304 participants · Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI